CDK4/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance
{{output}}
The Cyclin-dependent kinase 4/6 (CDK4/6) complex orchestrates the critical G1-to-S phase transition by phosphorylating the Retinoblastoma protein (Rb), establishing it as a validated therapeutic target in oncology. The clinical deployment of ATP-competitive in... ...
